Dr. Anton Lindberg is a staff scientist with the Brain Health Imaging Centre and the Azrieli Centre for Neuro-Radiochemistry at CAMH.
He earned his PhD in medical science in 2019 from Karolinska Institute in Stockholm, Sweden and with the National Institute of Mental Health (NIMH) in Bethesda, Maryland, under the supervision of Professor Christer Halldin and Dr. Victor Pike. Prior to his PhD training, he worked as an organic chemist in central nervous system (CNS) drug discovery at AstraZeneca Pharmaceuticals. His PhD dissertation focused on development of novel serotonin 5-HT1B PET radioligands, with the goal of evaluating the difference between antagonist and agonist positron emission tomography (PET) radioligands ability to quantify changes in endogenous neurotransmitter concentrations. After completing his PhD, he trained as a postdoctoral fellow (2019-2021) at CAMH under the supervision of Professor Neil Vasdev. During his postdoctoral training he worked on developing novel radiolabeling strategies using [11C]CO2 and [11C]CO as well as development of a new generation of 4R-tau PET radiotracers.
Areas of Research
Dr. Anton Lindberg’s research includes development of novel radiolabeling strategies using fluorine-18 and carbon-11. Additionally, he is also involved in the medicinal chemistry of novel PET radiotracers for PET imaging of new targets in the central nervous system.
View Dr. Lindberg’s publications on Publons.com.